Effects of bosutinib treatment on renal function in patients with Philadelphia chromosome-positive leukemias

Conclusions Long-term bosutinib treatment is associated with an apparently reversible decline in renal function with frequency and characteristics similar to renal decline observed with long-term imatinib treatment. Patients with risk factors for grade ≥3b eGFR should be monitored closely. Both trials are registered at clinicaltrials.gov (phase 1/2: NCT00261846; phase 3: NCT00574873). Teaser We evaluated incidence of renal adverse events and estimated glomerular filtration rate in patients with Philadelphia chromosome-positive leukemias receiving first-line bosutinib (n=248) or imatinib (n=251), or second-line or later bosutinib (N=570). Results demonstrate that long-term bosutinib treatment is associated with an apparently reversible decline in renal function with frequency and characteristics similar to those observed with long-term imatinib.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research